Florida biotech billionaire settles SEC stock manipulation case

By Jonathan Stempel

NEW YORK: Florida biotechnology billionaire Phillip Frost has agreed to pay $5.52 million to settle U.S. Securities and Exchange Commission civil charges over his alleged role in “pump-and-dump” schemes that left investors with virtually worthless stock.

The settlement requires Frost, the chairman and chief executive of Miami-based Opko Health Inc, to pay a $5 million fine and about $523,000 representing alleged ill-gotten gains and interest, according to a Thursday filing in Manhattan federal court.

Frost also accepted restrictions on trading penny stocks. Opko agreed to pay a $100,000 fine in a related settlement.

Neither defendant admitted or denied wrongdoing in agreeing to the settlements, which will end “potentially expensive, contentious and time-consuming litigation,” Frost said in a statement provided by Opko. Court approval is required.

A lawyer for Frost had no immediate additional comment.

Frost was among 10 people and 10 associated entities charged by the SEC on Sept. 7 with involvement from 2013 to 2018 in the manipulation of three companies’ share prices.

The SEC accused various defendants of buying large blocks of penny stocks at steep discounts, promoting the shares, and then quietly selling their stock at inflated prices, generating more than $27 million of improper gains.

Frost was allegedly involved in two of the schemes, the SEC said.

Now 82, Frost is worth $1.9 billion, Forbes magazine said on Thursday.

He had been chairman and chief executive of Ivax Corp before selling that drugmaker for $7.4 billion in 2006 to Israel-based Teva Pharmaceutical Industries Ltd, where he later served as chairman.

  • Related Posts

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India